Want to see SCNI full AI Analyst Report?
Scinai Immunotherapeutics (SCNI) AI Stock Analysis
Scinai Immunotherapeutics
(NASDAQ:SCNI)
Persistent losses and cash burn are the largest constraints, while the improved balance sheet and early CDMO revenue traction provide some support. Weak technical momentum and the absence of meaningful earnings-based valuation support keep the overall score low, despite oversold technical conditions and constructive commercial guidance.
Scinai Immunotherapeutics (SCNI) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $243.79K
- Dividend Yield
- ―
- Average Volume (3M)
- 2.15M
- Price to Earnings (P/E)
- 0.0
- Beta (1Y)
- 1.29
- Revenue Growth
- 30.12%
- EPS Growth
- -165.46%
- Country
- US
- Employees
- 45
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Scinai Immunotherapeutics Business Overview & Revenue Model
Company Description
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range o...
How the Company Makes Money
Publicly available, company-specific detail on Scinai Immunotherapeutics’ current revenue model and recurring revenue streams is not available in the information provided. null
Scinai Immunotherapeutics Earnings Call Summary
The call conveys a constructive strategic story: the Recipharm acquisition materially expanded Scinai's capabilities and produced early commercial traction (committed orders, invoicing and a U.S. engagement with ~$650k in post-quarter cash). However, near-term financials show meaningful operating and gross losses and a modest cash balance (~$2.85M), leaving the company reliant on successful conversion of orders, utilization improvements and additional funding. Management emphasizes disciplined R&D spending, use of non-dilutive funding and selective use of the $15M SEPA. Given the balance of promising commercial/strategic progress against short-term liquidity and operating loss challenges, the tone is cautiously optimistic but pragmatic.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management's guidance is focused on commercial execution and capital discipline: they are pursuing approximately $5.0M of CDMO revenue for 2026 and aim to convert ~$3.1M of committed customer orders (≈$1.6M Yavne / ≈$1.5M Jerusalem; ≈$2.1M invoiced as of Aug 10 and ≈$1.0M signed but not yet invoiced) into recognized revenue and higher utilization across Jerusalem and Yavne; liquidity stood at ≈$2.85M cash and restricted cash as of June 30, they received ≈$650k in cash/advances after June 30 from a U.S. clinical manufacturing engagement, and H1 results showed revenue ≈$949k (vs ≈$773k H1 2025), gross loss ≈$2.37M, operating loss ≈$4.6M, and a noncash bargain purchase gain ≈$6.4M that produced net income ≈$1.57M; management plans to emphasize repeat business, non-dilutive funding and selective use of the existing $15M SEPA (post‑effective amendment; advances priced at 97% of VWAP) while prioritizing R&D spend.
Scinai Immunotherapeutics Financial Statement Overview
Summary
Revenue is growing and the balance sheet has improved, but persistent operating losses and substantial negative operating and free cash flow remain major risks. The financial performance score reflects an income statement score of 38, balance sheet score of 62, and cash flow score of 24.
Income Statement
38NegativeBalance Sheet
62PositiveCash Flow
24Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.49M | 1.31M | 658.00K | 0 | 0 | 0 |
| Gross Profit | -3.77M | -2.65M | -580.00K | 0 | 0 | -747.65K |
| EBITDA | -6.66M | -6.53M | -6.99M | -2.19M | -5.23M | -10.32M |
| Net Income | -2.64M | -8.31M | 4.80M | -6.50M | -5.80M | -12.38M |
Balance Sheet | ||||||
| Total Assets | 17.17M | 11.63M | 13.45M | 17.47M | 27.07M | 32.04M |
| Cash, Cash Equivalents and Short-Term Investments | 2.85M | 1.66M | 1.96M | 4.87M | 14.07M | 17.37M |
| Total Debt | 3.58M | 2.27M | 2.09M | 20.56M | 21.54M | 29.23M |
| Total Liabilities | 5.44M | 3.52M | 3.47M | 22.04M | 28.83M | 31.05M |
| Stockholders Equity | 11.73M | 8.10M | 9.98M | -4.57M | -1.76M | 982.00K |
Cash Flow | ||||||
| Free Cash Flow | -7.53M | -6.05M | -6.35M | -10.02M | -8.10M | -7.57M |
| Operating Cash Flow | -7.40M | -6.03M | -6.33M | -9.38M | -7.26M | -7.43M |
| Investing Cash Flow | 2.64M | -24.00K | -12.00K | -637.00K | -836.00K | -139.00K |
| Financing Cash Flow | 6.53M | 5.77M | 3.44M | 1.09M | 6.78M | 21.43M |
Scinai Immunotherapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCNI, the sentiment is Negative. The current price of 0.46 is below the 20-day moving average (MA) of 0.84, below the 50-day MA of 1.53, and below the 200-day MA of 4.46, indicating a bearish trend. The MACD of -0.30 indicates Negative momentum. The RSI at 22.65 is Positive, neither overbought nor oversold. The STOCH value of 4.56 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SCNI.
Scinai Immunotherapeutics Risk Analysis
Scinai Immunotherapeutics disclosed 78 risk factors in its most recent earnings report. Scinai Immunotherapeutics reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksScinai Immunotherapeutics Peers Comparison
Overall Rating
- SCNI43Neutral
GTBP42Neutral
Financial Indicators
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SCNI | Scinai Immunotherapeutics Ltd. Sponsored Adr | 0.47 | -10.83 | -95.83% | |
| GTBP | Gt Biopharma, Inc. | 5.32 | -10.13 | -65.56% | |
| ADTX | Aditxt, Inc. | 0.04 | -1123.16 | -100.00% | |
| CERO | Cero Therapeutics Holdings, Inc. | 0.01 | -0.09 | -90.00% | |
| PBM | Psyence Biomedical Ltd. | 3.31 | -13.81 | -80.67% | |
| CDT | Cdt Equity Inc. | 0.07 | -15249.93 | -100.00% |
Scinai Immunotherapeutics Corporate Events
Scinai Immunotherapeutics Extends Cash Runway on New CDMO Deal and October Financing
On October 20, 2026, Scinai Immunotherapeutics reported that a new CDMO agreement with a U.S.-based Nasdaq-listed biopharmaceutical client and recently completed equity financings have significantly expanded its contracted business and strengthened l...
Scinai Immunotherapeutics Closes $4 Million Private Placement and Warrant Deal
On October 16, 2026, Scinai Immunotherapeutics closed a $4.0 million financing, combining a private placement of American Depositary Shares and an inducement for immediate exercise of existing warrants, which also generated new Series A-1 warrants. T...
Scinai Immunotherapeutics Secures $4 Million via Private Placement and Warrant Inducement
On October 13, 2026, Scinai Immunotherapeutics entered into a securities purchase agreement with an existing institutional life sciences investor for a private placement of 2,458,334 American Depositary Shares or pre-funded warrants, plus Series A-1...
Scinai Immunotherapeutics Secures $5.1 Million CDMO Deal, Tripling Committed Orders
Scinai Immunotherapeutics announced on October 13, 2026 that its subsidiary Scinai Biopharma Services has signed a definitive development and clinical manufacturing agreement worth approximately $5.1 million in committed base service fees with a U.S....
Scinai Immunotherapeutics Restores Nasdaq Minimum Bid Price Compliance
On September 21, 2026, Scinai Immunotherapeutics announced that Nasdaq has confirmed the company regained compliance with the $1.00 minimum bid price requirement under Listing Rule 5550(a)(2), closing a months-long listing risk. The decision followed...
Scinai Shifts Capital to NanoAb Platform and CDMO Growth After Ending PC111 Deal
On September 8, 2026, Scinai Immunotherapeutics announced it had allowed its option and license agreements with PinCell regarding the preclinical program PC111 to expire on August 31, 2026, ending its involvement without securing new funding. The com...
Scinai Highlights First-Half CDMO Expansion and Recipharm Israel Gain in August 2026 Update
In a business update released on August 24, 2026, Scinai Immunotherapeutics reported growing momentum in its CDMO arm, with committed customer orders reaching about $3.1 million as of August 16, 2026 and an expanded clinical manufacturing and CMC pro...
Scinai Immunotherapeutics Sets 1-for-10 ADS Ratio Change to Support Nasdaq Compliance
On August 19, 2026, Scinai Immunotherapeutics announced that, effective August 21, 2026, it will change the ratio of its American Depositary Shares so that one ADS will represent 40,000 ordinary shares instead of 4,000, a move that functions as a one...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 22, 2026